Ketamine
| Evidence Level: L2 | Predicted Indications: 1 |
Table of Contents
Ketamine: From Anaesthesia to Headache Disorder
One-Sentence Summary
Ketamine is an injectable anaesthetic and analgesic agent that is widely marketed in India as a single-ingredient product. The TxGNN model predicts it may be effective for headache disorder, with 9 clinical trials and 20 publications currently supporting this direction. Several of the trials are small, and one Phase 3 trial is still recruiting.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the data compiled for this report (the licence records contain no approved indication text) |
| Predicted New Indication | Headache disorder |
| TxGNN Prediction Score | 0.9933 |
| Evidence Level | L2 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Ketamine is an NMDA receptor antagonist. Currently, detailed mechanism of action data is not available in the data compiled for this report, so the following explanation rests on general pharmacology rather than the supplied record.
Glutamatergic signalling and central sensitisation contribute to migraine, cluster headache and other chronic headache disorders. Blocking NMDA receptors may dampen cortical spreading depression and trigeminovascular pain transmission. At sub-dissociative doses, ketamine also produces analgesia by modulating descending pain pathways.
This mechanism is plausible and fits the clinical signals seen in the emergency department and chronic headache trials. The high TxGNN score supports the prediction but is not clinical evidence in itself.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03081416 | Phase 3 | Completed | 80 | THINK trial: intranasal ketamine vs standard therapy for primary headache in the emergency department; outcome not shown in the registry record |
| NCT05306899 | Phase 3 | Recruiting | 56 | KetHead: placebo-controlled trial of high-dose IV ketamine infusion for chronic daily headache; no results yet |
| NCT02657031 | Phase 4 | Completed | 54 | Low-dose ketamine vs prochlorperazine for headache in the emergency department |
| NCT04814381 | Phase 4 | Completed | 93 | Single ketamine infusion combined with magnesium sulfate for refractory chronic cluster headache |
| NCT03221569 | Phase 4 | Unknown | 60 | Sub-dissociative ketamine vs ketorolac for tension-type headache |
| NCT02697071 | Not applicable | Completed | 34 | Randomised placebo-controlled trial of sub-dissociative ketamine for acute migraine-type headache |
| NCT04179266 | Phase 1/2 | Completed | 23 | Proof-of-concept study of intranasal ketamine spray in chronic cluster headache |
| NCT04860713 | Phase 4 | Completed | 5 | Oral ketamine plus aspirin vs rimegepant in emergency headache; too small to be informative |
| NCT02403687 | Not applicable | Completed | 300 | General analgesic compound study; only indirectly relevant to headache |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41321235 | 2026 | Guideline | Headache | American Headache Society 2025 update on parenteral drugs for acute migraine in the emergency department |
| 34703891 | 2021 | Systematic review | J Dent Anesth Pain Med | Efficacy of ketamine in migraine and other primary headache disorders vs placebo and active comparators |
| 36310189 | 2023 | Systematic review and meta-analysis | J Neurol | Preventive treatments for refractory chronic cluster headache |
| 35356451 | 2022 | Retrospective cohort | Front Neurol | Efficacy, duration and safety of IV lidocaine and ketamine infusions for inpatient headache treatment |
| 34919214 | 2022 | Review | Drugs | Drug treatment of cluster headache, including acute and preventive options |
| 32189074 | 2020 | Review | Curr Neurol Neurosci Rep | Emergency department and inpatient headache management in adults |
| 32410204 | 2020 | Review | Curr Neurol Neurosci Rep | Emergency department and inpatient headache management in children and adolescents |
| 38870050 | 2024 | Review | Expert Rev Neurother | Pharmacotherapy for trigeminal neuralgia; ketamine mentioned as a possible adjuvant |
Many other retrieved publications concern ketamine in depression and are not directly relevant to headache.
India Market Information
All 20 registrations are valid single-ingredient injectable products. The five main ones are listed below; none of the licence records contains approved indication text.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 117090 | Ketam 50mg Injection | Vial of 2 ml injection | Not stated |
| 119150 | Ketanik Injection | Vial of 10 ml injection | Not stated |
| 116674 | Ketmin 100mg Injection | Vial of 2 ml injection | Not stated |
| 170405 | Oblar 500mg Injection | Vial of 10 ml injection | Not stated |
| 118514 | Ketalar 10mg Injection | Vial of 20 ml injection | Not stated |
Safety Considerations
- Disease associations flagged in the knowledge graph (these come from the TxGNN knowledge graph, not from label text): hypertension and hypertensive disorder, stroke and cerebrovascular disorder, cerebral infarction, myocardial infarction, myocardial ischaemia and coronary artery disease, intracranial hypertension, ocular hypertension, hyperthyroidism and Graves disease, respiratory failure, delirium, substance abuse or dependence, and hemoglobinopathy.
- Drug interactions: 111 interactions were identified. Moderate-level examples include morphine, diphenoxylate, dronabinol, metoclopramide, nabilone, opium, sibutramine, phentermine, ephedrine, fenfluramine, isometheptene and topical epinephrine. Several other pairings, such as atropine, famotidine, omeprazole and ondansetron, have an unclassified severity.
Please refer to the package insert for key warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Ketamine is already widely marketed in India, and several completed randomised and comparator trials in emergency and chronic headache point in a consistent direction. These trials are small, their outcomes were not available in the data compiled for this report, and the large Phase 3 trial is still recruiting. The cardiovascular and intracranial-pressure flags also call for careful patient selection.
To proceed, the following is needed:
- Package insert warnings and contraindications, which are currently missing and block the safety screening
- Confirmed outcome results from the completed Phase 3 THINK trial, and results from the KetHead trial once available
- Detailed mechanism of action data from an authoritative source
- Approved indication text for the Indian licences
- A patient-selection and monitoring plan for people with hypertension, cardiovascular or cerebrovascular disease, raised intracranial pressure, or substance-use history
- An assessment of dose, route and setting (emergency department vs infusion centre), since no route compatibility analysis has been completed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.